National Cancer Center

Nec Corporation

Oncotherapy Science, Incorporated

Fujifilm Corporation

Ryuji Hamamoto

Yutaka Saito

Kenichi Kamijo

Kimiyasu Takoh

Ikuma Takahashi

Motoyasu Okutsu

Masayoshi Yamada

Masahiro Saikou

Maki Sano

Hitoshi Imaoka

Chiemi Tanaka

Yusuke Nakamura

Shuichi Nakatsuru

Yoichi Furukawa

Shota Ohtsuka

Tatsu Kimura

Akira Togashi

Kazuma Kobayashi

Mototaka Miyake

Provided are an information processing device, a display method, and a program that allow to easily grasp during examination that a lesion is captured how long before from now which is detected by detection processing for an image captured by an endoscope. An information processing device includes: an image acquisition unit configured to sequentially acquire a current image captured by an endoscope; a lesion detection unit configured to sequentially perform detection processing of a lesion site on the images sequentially acquired by the image acquisition unit; and a display control unit configured to display, on a display device, a degree of lapse of time up to a current time from a capturing time of the image in which the lesion site is detected by the lesion detection unit.

Information processing device, display method, and non-transitory computer-readable medium for storing a program for lesion detection processing supporting decision making using machine learning

An information processing apparatus () detects an abnormal region () from a moving image frame (). The abnormal region () is a region that is estimated to represent an abnormal part inside a body of a subject. The information processing apparatus () generates and outputs output information based on the number of detected abnormal regions ().

Information processing apparatus, control method, and program

An annotation support apparatus manages a medical image on the basis of an attribute of each medical image, using a hierarchical structure that has one medical image as a node and includes a medical image hierarchy to which a node of the medical image belongs and at least one of an upper hierarchy higher than the medical image hierarchy or a lower hierarchy lower than the medical image hierarchy. The annotation support apparatus includes: an image acquisition unit that acquires the medical image; a display unit; an annotation input receiving unit that receives designation of any one of the node of the medical image or a node associated with the node of the medical image in the hierarchical structure and an input of annotation information related to the designated node; and an annotation storage unit that stores the annotation information to be associated with the designated node.

Annotation support apparatus, annotation support method, and annotation support program

An information processing apparatus () detects an abnormal region () in each of a plurality of video frames () constituting video data () in which the inside of a body is captured. The information processing apparatus () outputs output information related to the detected abnormal region (). Herein, the information processing apparatus () starts outputting of the output information when a detection score based on a proportion of the number of the video frames () in which the abnormal region () is detected becomes equal to or more than a first threshold value in a state where outputting of the output information is not being performed. Further, the information processing apparatus () ends outputting of the output information when the detection score becomes equal to or less than a second threshold value in a state where outputting of the output information is being performed.

Information processing apparatus, control method, and non-transitory storage medium

Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.

PRMT1 for target genes of cancer therapy and diagnosis

The present invention relates to methods for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of VEGFR1 by SMYD3. The invention further provides methods and pharmaceutical compositions for treating and preventing colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.

Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3

The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.

Methods of modulating SMYD3 for treatment of cancer

Growing community of inventors

Tokyo, Japan

Ryuji Hamamoto